The legacy of Thalidomide will always remain a part of our company’s history. We will never forget what happened, and we deeply regret the wide-ranging consequences for the people affected and their families. On this page, you will find information about Thalidomide and how Grünenthal currently provides support to Thalidomide-affected people.
Gabriel Baertschi, CEO Grünenthal
The history of the Thalidomide tragedy
Thalidomide: The medication and its consequences
11/27/2021
60 Years after the market withdrawal: Dr. Michael Wirtz apologises to those affected on behalf of his family
On the occasion of 60 years after the market withdrawal of Thalidomide, Dr. Michael Wirtz, shareholder of Grünenthal, apologised to those affected and their families on behalf of his family. As company, we welcome this step.
More12/14/2020
The end of the criminal proceedings against Grünenthal: 50 years later
50 years ago today, the Aachen Regional Court terminated the Thalidomide proceedings against nine Grünenthal senior employees. The criminal trial is still considered one of the most complex and costly proceedings in German legal history. The legal and medical questions concerning the Thalidomide tragedy were complex and difficult to answer.
MoreContact
Contact information for journalists and Thalidomide-affected people
Fabia Kehren
Contact for the public
Global Communications Grünenthal GmbH
Phone +49 (0) 241 569 3269
E-Mail Fabia.Kehren@grunenthal.com
Tom Hermes
Contact for people affected by Thalidomide
The Grünenthal Foundation for the Support of Thalidomide-Affected People
Phone +49 (0) 241 569 2742
